The U.S.Food and Drug Administration issued a Complete Response Letter for Mesoblast’s Biologics License Application for Ryoncil (remestemcel-L).

The U.S. Food and Drug Administration is wrapping up the month of September with a few PDUFA dates, including an approval review of Aquestive’s Libervant for the management of seizure clusters in epilepsy.